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It has recently been suggested that the low-frequency c.136–
14_136–13insC variant in high-mobility group A1 (HMGA1) may
strongly contribute to insulin resistance and type 2 diabetes risk.
In our study, we attempted to conﬁrm that HMGA1 is a novel type
2 diabetes locus in French Caucasians. The gene was sequenced
in 368 type 2 diabetic case subjects with a family history of type 2
diabetes and 372 normoglycemic control subjects without a family
history of type 2 diabetes. None of the 41 genetic variations iden-
tiﬁed were associated with type 2 diabetes. The lack of associa-
tion between the c.136–14_136–13insC variant and type 2
diabetes was conﬁrmed in an independent French group of
4,538 case subjects and 4,015 control subjects and in a large
meta-analysis of 16,605 case subjects and 46,179 control subjects.
Finally, this variant had no effects on metabolic traits and was
not involved in variations of HMGA1 and insulin receptor (INSR)
expressions. The c.136–14_136–13insC variant was not associ-
ated with type 2 diabetes in individuals of European descent.
Our study emphasizes the need to analyze a large number of
subjects to reliably assess the association of low-frequency var-
iants with the disease. Diabetes 61:524–530, 2012
Insulin resistance and pancreatic b-cell dysfunctionare the two physiologic hallmarks of type 2 diabetes,and the expectation was that the majority of sus-ceptibility loci identiﬁed in genome-wide association
studies (GWASs) would map to either of these diabetes-
related phenotypes. Yet, the majority of these loci can be
directly mapped to the pancreatic b-cell or are of unknown
biologic consequence (1). Few loci were associated with
insulin resistance (2,3). Furthermore, the known common
variants account for ,10% of the overall estimated genetic
contribution to type 2 diabetes predisposition (3). There is
obviously a “dark matter” that remains to be discovered
(4). A growing number of researchers are turning to rare
genetic changes with strong effects as important contrib-
utors (5–8). Because whole-genome sequencing requires
computational power and remains costly for large case-
control studies, candidate gene sequencing may be an ef-
fective approach to identify rare and low-frequency variants
associated with common diseases.
In 2005, Foti et al. (9) observed that lack of HMGA1
causes insulin resistance and diabetes in humans. This
gene encodes a nonhistone protein that binds on AT-rich
segments in the minor groove of DNA and regulates gene
transcription (10,11). HMGA1 is a positive regulator of
both insulin receptor (INSR) and insulin-like growth factor-I
receptor (IGF-IR) genes and is induced by the Wnt/
b-catenin pathway, which is known to play a key role in
type 2 diabetes risk (12–16). In humans, two rare Mende-
lian mutations were identiﬁed only in diabetic patients and
associated with impaired HMGA1 expression: a hemi-
zygous deletion of HMGA1 (two carriers from the same
family) and a heterozygous single-nucleotide deletion in
the 39 untranslated region of HMGA1 (c.*369del) (9).
Chiefari et al. (17) recently observed that a low-frequency
variant in HMGA1 (c.136–14_136–13insC) was strongly
associated with type 2 diabetes risk and decreased ex-
pression of HMGA1 and INSR genes. All these elements
suggest that rare variants located in this gene can be
strongly associated with type 2 diabetes through their ef-
fects on insulin resistance. However, extensive analysis of
the HMGA1 gene in additional populations is necessary to
validate previous ﬁndings and identify novel variants po-
tentially associated with type 2 diabetes risk (18).
RESEARCH DESIGN AND METHODS
Study populations. For the sequencing of the HMGA1 gene, a screening
group of 368 French type 2 diabetic case subjects and 372 French normogly-
cemic control subjects was selected. The case subjects were composed of
those with at least two ﬁrst-degree relatives with type 2 diabetes, collected by
the UMR CNRS 8199 laboratory. French control subjects were composed of
those from the general population study Data from an Epidemiological Pro-
spective Study on the Insulin Resistance Syndrome (DESIR), who were se-
lected because they remained normoglycemic after 9 years of follow-up and
had no family history of diabetes (19).
The c.136–14_136–13insC variant was also analyzed in a replication group
of 4,538 French type 2 diabetic case subjects and 4,015 French normoglycemic
control subjects (Table 1). Type 2 diabetic case subjects were composed of those
from the UMR CNRS 8199 laboratory (n = 377), the Non-Insulin-Dependent Di-
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and Ramipril (DIABHYCAR) study (n = 2,095), the DESIR study (n = 295), the
Biological Atlas of Severe Obesity (ABOS) study (n = 117), and the Corbeil-
Essonnes Hospital (n = 1,654) (20). Control subjects were composed of sub-
jects from the UMR CNRS 8199 laboratory (n = 1,306), the DESIR study (n =
2,291), the ABOS study (n = 207), and the Fleurbaix-Laventie Ville Santé study
(n = 211). The DIABHYCAR study design and results have been reported
(20,21). Participants were selected on the basis of type 2 diabetes, treatment
with oral antidiabetic agents on enrollment, high urinary albumin concentra-
tion, age $50 years, and serum creatinine concentration #150 mmol/L. French
patients were selected by their general practitioners, and $98% were Cauca-
sian (20). The ABOS study was ﬁrst designed to analyze the association be-
tween glycemic or ponderal status and tissue gene expression and has been
extended to provide longitudinal follow-up and samplings of a cohort of 900
morbid obese patients subjected to bariatric (weight loss) surgery. The
Fleurbaix-Laventie Ville Santé study is a longitudinal epidemiologic study on
the determinants of weight gain (22).
All type 2 diabetic case subjects and normoglycemic control subjects of this
study were deﬁned according to the 2003 American Diabetes Association
criteria (type 2 diabetes: fasting plasma glucose $7.0 mmol/L or treated for
diabetes; normoglycemic: fasting glucose ,5.6 mmol/L). Only French Cau-
casians were analyzed. Informed consent was obtained from each subject, and
our study protocol was approved by local ethics committees.
GWAS data were made available from the DIAGRAM consortium (3). All
sample characteristics and statistics remain the same as previously described
(3). However, any overlapping samples from the Diabetes Gene Discovery
Group (DGDG) study (French samples) were excluded. Total sample size in
the seven-study meta-analysis remained at 7,451 type 2 diabetic case subjects
and 38,290 control subjects. Correlations between polymorphisms and the
c.136–14_136–13insC variant were estimated using pilot release data from the
CEU population of the 1000 Genomes project (23).
Sequencing. Overall, 4.5 kb of the HMGA1 gene were sequenced, including
the entire promoter region (2591 base pairs [bp] before the transcription start
site 1 to +980 bp after), 8 exons, and 16 intron-exon junctions and untranslated
regions. HMGA1 gene structure was based on RefSeq transcripts (National
Center for Biotechnology Information, Bethesda, MD) (NM_002131, NM_145899,
NM_145901, NM_145902, NM_145903, NM_145905), genomic sequence (Gen-
Bank NT_007592.15). Primers were designed using Primer-BLAST (National
Center for Biotechnology Information) and were validated not to amplify the
pseudogene regions using In-Silico PCR (University of California, Santa Cruz,
CA) (Supplementary Table 1). PCR ampliﬁcations were puriﬁed using Agencourt
AMPure (Agencourt Bioscience Corporation, Beverly, MA) on Biomex NX
(Beckman Coulter, Fullerton, CA) after validation of a single band of excepted
size on agarose gel. Puriﬁed PCR ampliﬁcation products were then used for
sequence reaction with Big Dye Terminator Cycle Sequencing Ready Reaction
Kit 3.1 (Applied Biosystems, Foster City, CA). Sequence products were puriﬁed
with Agencourt CleanSEQ (Agencourt Bioscience Corporation) on Biomek
NX read on an ABI Prism 3730XL DNA Sequencer and assembled and ana-
lyzed with Variant Reporter, Seqscape (Applied Biosystems), and Sequencher
software (Gene Codes Corporation, Ann Arbor, MI). All variants were vali-
dated by resequencing of forward and reverse strands.
Genotyping. Genotyping was performed using the High Resolution Melting
(HRM) method using MeltDoctor HRM Master Mix (Applied Biosystems) on
a Lightcycler 480 (Roche, Indianapolis, IN). HRM curve analysis was performed
on LightCycler 480 software, and positive signals were conﬁrmed by se-
quencing. There was a concordance rate of .99% between genotyping and
sequencing results for the 368 type 2 diabetic case subjects and 372 normo-
glycemic control subjects of the screening study.
Intermediate metabolic traits. BMI is the weight in kilograms divided by the
square of the height in meters. The homeostasis model assessment (HOMA)-2–
insulin resistance and HOMA2-B indices were calculated using the HOMA
calculator based on fasting glucose and fasting insulin levels in subjects in
a steady-state situation (fasting plasma glucose: 3–25 mmol/L; fasting plasma
insulin: 20–400 pmol/L; available at http://www.dtu.ox.ac.uk/homacalculator).
HbA1c was only available in a subset of the DESIR and UMR CNRS 8199
samples. The insulinogenic index (IGI) was calculated on the basis of the oral
glucose tolerance test (OGTT) measures as IGI = (30 min plasma insulin 2
fasting plasma insulin)/30 min plasma glucose, where plasma insulin is in
pmol/L and plasma glucose is in mmol/L (24). The insulin sensitivity index
(ISI) was calculated on the basis of OGTT measures as ISI = 10,000/=(fasting
plasma glucose3 fasting plasma insulin3mean OGTT glucose3mean OGTT
insulin), where plasma insulin and OGTT insulin are in mU/L and plasma
glucose and OGTT glucose are in mg/dL (25). The disposition index (DI) was
calculated on the basis of OGTT measures in subjects with a fasting plasma
glucose $70 mg/dL as DI = ISI 3 100 3 30 min plasma insulin 3 (30 min
plasma glucose 3 [30 min plasma glucose – 70 mg/dL]), where plasma insulin
is in mU/L and plasma glucose is in mg/dL (26). Indices based on OGTT mea-
sures were only available for a subset of UMR CNRS 8199 samples. Waist-to-hip
ratio was calculated as waist circumference in centimeters divided by hip cir-
cumference in centimeters and was only available in DESIR and UMR CNRS
8199 samples. Only normoglycemic subjects were analyzed to avoid possible
modifying effects of type 2 diabetes and treatments on metabolic traits.
Expression study. The expression study was conducted in 149 Swedish
obesity-discordant siblings (included in the Swedish Obese Subjects [SOS] Sib
Pair study) using Merlin under a dominant genetic model (27,28). Average
family size was 4.34, and median age (ﬁrst to third quartiles) was 44 years (36–
62). Gene expression data were available from 347 siblings, and peripheral
blood was available from all subjects. Gene expression was measured in
subcutaneous adipose tissue using the Affymetrix Human U133PLUS2.0 mi-
croarrays for HMGA1 (probe-sets 206074_s_at and 210457_x_at) and INSR
(probe-sets 213792_s_at, 207851_s_at, 226450_at, 226212_s_at, and 226216_at).
A Genetic Power Calculator was used to estimate the power of our study in
identifying association between the c.136–14_136–13insC variant and HMGA1
and INSR gene expression levels (29). To this aim, we assessed the heritability
of the HMGA1 and INSR transcription levels on the Swedish sample and used
observations from the study by Chiefari et al. (17) to estimate both the minor
allele frequency (MAF) of the c.136–14_136–13insC variant and its effects on
the gene expression levels. The association study was carried out by ﬁtting
a linear regression model to each probe-set within a variance component
framework to account for correlation between gene expression levels within
each family (30).
Statistical analyses. Given the low allele frequency of the c.136–14_136–
13insC variant, only the dominant genetic model of inheritance was consid-
ered. In our screening analysis, the statistical power of our study design was
sufﬁcient to detect low-frequency variants with strong effect sizes (type I error
rate of 0.05) (Supplementary Fig. 1). MAFs between case subjects and control
subjects were compared using the x2 test and Monte Carlo simulations (n =
2,000). Associations of the c.136–14_136–13insC variant with type 2 diabetes
and age at diagnosis were analyzed using logistic regression and linear re-
gression models, respectively. No associations between the c.136–14_136–
13insC variant and the confounding factors (i.e., age at examination, sex, and
BMI) were detected using adjusted linear and logistic regression models (P =
0.39, P = 0.42, P = 0.21, respectively). Furthermore, these confounding factors
had no inﬂuence on the association between the c.136–14_136–13insC variant
and type 2 diabetes (P = 0.81, P = 0.87, P = 0.59, respectively). No between-
cohort heterogeneity in the genotype distributions of the c.136–14_136–13insC
variant and no deviation from Hardy-Weinberg equilibrium were detected
(Supplementary Table 2). Linear regression models were used to compare
quantitative intermediate traits between normoglycemic and type 2 diabetic
subjects. All statistical models were adjusted for age, sex, and BMI (if ap-
propriate). When necessary, metabolic traits were log-transformed to satisfy
the assumption of normality. Heterogeneity between studies was assessed by
the Woolf’s test and quantiﬁed by the Higgins statistic (I2) (31,32). Because of
TABLE 1
Association between the c.136–14_136–13insC variant and type 2 diabetes in French individuals
Study Glycemic status n 2/2 –/C C/C MAF (%) H-W OR (95% CI) P
Screening Normoglycemic 372 351 21 0 2.82 0.99 0.91 (0.24–3.36) 0.88
Type 2 diabetes 368 357 11 0 1.49 0.99
Replication Normoglycemic 4,015 3,808 206 1 2.59 0.52 1.12 (0.87–1.44) 0.38
Type 2 diabetes 4,538 4,282 256 0 2.82 0.06
Screening + replication Normoglycemic 4,387 4,159 227 1 2.61 0.37 1.07 (0.84–1.37) 0.57
Type 2 diabetes 4,906 4,639 267 0 2.72 .0.05
ORs (95% CI) were estimated using logistic regression models adjusted for age, sex, and BMI. H-W, deviation from Hardy-Weinberg equilib-
rium (P value).
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strong heterogeneity between previous and current ﬁndings, we applied a
random-effects meta-analysis to estimate summary odds ratios (ORs) 1, 3,
and 4 (33). However, a ﬁxed-effects meta-analysis was performed to estimate
the summary OR 2 given that no heterogeneity was observed between
summary OR 1 and DIAGRAM data. Statistical power was assessed using
Quanto (version 1.2.4). All P values were two-sided. The Bonferroni cor-
rection was calculated to address the problem of multiple comparisons.
SPSS (v. 14.0.2; SPSS, Chicago, IL) and R statistics (v. 2.10.1) were used for
general statistics.
RESULTS
Screening of the HMGA1 gene. The HMGA1 gene was
sequenced in 368 type 2 diabetic case subjects having at
least two ﬁrst-degree relatives with type 2 diabetes and 372
normoglycemic control subjects prospectively followed
during 9 years and without family history of diabetes.
Overall, 41 genetic variants were detected, including four
variants (c.136–14_136–13insC, rs41269028, rs2780219, and
rs17038619) previously identiﬁed by Chiefari et al. (17)
(Fig. 1 and Supplementary Table 3). None of them were
differentially distributed between normoglycemic control
subjects and type 2 diabetic case subjects. However, the
c.136–14_136–13insC C allele tended to be more frequent
in control subjects compared with type 2 diabetic case
subjects (MAF 2.82 vs. 1.49%, P = 0.09) (Table 1, Supple-
mentary Table 3, and Supplementary Fig. 2). Given that
this low-frequency variant was supposed to be strongly
associated with type 2 diabetes, we veriﬁed this hypothesis
by analyzing larger groups of case and control subjects.
Association of the c.136–14_136–13insC variant and
type 2 diabetes. An additional 4,538 type 2 diabetic case
subjects and 4,015 normoglycemic control subjects were
genotyped for the c.136–14_136–13insC variant. Genotype
distributions and ORs are reported in Table 1. No associ-
ation between the c.136–14_136–13insC variant and type 2
diabetes risk was observed (screening + replication groups:
OR 1.07, CI 0.84–1.37, P = 0.57). Furthermore, no associa-
tion between the c.136–14_136.13insC variant and the age at
diagnosis was observed (P = 0.61). Given that Chiefari et al.
(17) analyzed two independent groups of Italian control
subjects and one group of Italian type 2 diabetic patients,
we performed two meta-analyses on the association of the
c.136–14_136–13insC variant and type 2 diabetes risk
(dominant model of inheritance) including either control
group 1 (n = 2,544, personal interviews to determine the
lack of family history of type 2 diabetes and related con-
ditions) or control group 2 (n = 784, self-reported medical
questionnaire).
By including the Italian control group 1, we detected
a strong heterogeneity between studies (Woolf test: x2 =
67.08, df = 2, P = 2.66 3 10215; Higgins test: I2 = 97% [94%;
98.5%]). In a total of 9,154 case subjects and 7,889 control
subjects of European descent (Italian, U.S., and French),
no association between the c.136–14_136–13insC variant
and type 2 diabetes was detected in our meta-analysis
(summary OR 1 = 2.95, 95% CI 0.76–11.54, P = 0.12) (Fig. 2).
By using CEU data generated from the 1000 Genomes pilot
project, we also identiﬁed 10 polymorphisms that were
perfectly correlated (r2 = 1) with the c.136–14_136–13insC
variant (Supplementary Table 4). Pairwise correlations (r2)
between these 10 polymorphisms were high in HapMap 3
(0.77–1.00). Disease association statistics were available for
these polymorphisms from a recently published DIAGRAM
consortium meta-analysis of 8,130 type 2 diabetic case
subjects and 38,987 control subjects (3). After exclusion of
samples already tested in this present study, the total
sample size was 7,451 case subjects and 38,290 control
subjects. Disease association test statistics ranged from
P = 0.31 to P = 0.89 for these 10 polymorphisms. The rare T
allele (HapMap CEU MAF = 2.7%) of the polymorphism
closest to the gene (rs9394200: distance ;5 kb), which tags
the risk-increasing insertion (OR 0.94, 95% CI 0.82–1.07,
P = 0.32), was selected to assess the signiﬁcance of this
signal in further meta-analysis. In a total of 16,605 case
subjects and 46,179 control subjects of European descent
(Italian, U.S., French, DIAGRAM consortium), no associ-
ation with type 2 diabetes was detected (summary OR 2 =
0.95, 95% CI 0.83–1.08, P = 0.44) (Fig. 2).
By including the Italian control group 2 (MAF 1.66%)
with another meta-analysis comprising 9,154 case subjects
and 6,129 control subjects of European descent (Italian, U.S.,
and French), a between-study heterogeneity was also
detected (Woolf test: x2 = 8.29, df = 2, P = 0.02; Higgins
FIG. 1. Genetic variants identiﬁed in theHMGA1 gene by sequencing. A total of 41 genetic variants were identiﬁed when sequencing theHMGA1 gene
in 368 type 2 diabetic subjects and 372 control subjects from our screening group of samples. Coding regions are represented by hatched boxes.
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test: I2 = 76% [20.6%; 92.7%]). Again, no association was
observed between the c.136–14_136–13insC variant and
type 2 diabetes (summary OR 3 = 1.49, 95% CI 0.98–2.26,
P = 0.06). Similar conclusions were reached when this
meta-analysis was extended to the DIAGRAM data (Italian,
U.S., French, DIAGRAM consortium) in 16,605 case subjects
and 44,419 control subjects of European origin (summary
OR 4 = 1.13, 95% CI 0.73–1.77, P = 0.58).
Effects on metabolic traits in normoglycemic control
subjects. Normoglycemic control subjects were then
analyzed for type 2 diabetes–related quantitative traits
(Table 2). Carrying a c.136–14_136–13insC C allele was
not found to inﬂuence fasting glucose, fasting insulin,
HOMA2 indices, IGI, ISI, DI, HbA1c, waist-to-hip ratio,
and BMI.
Effects on HMGA1 and INSR expressions. The HMGA1
and INSR expressions were assessed in the subcutaneous
adipose tissue of 347 siblings from the SOS Sib Pair study.
The expression levels of both INSR and HMGA1 in the
subcutaneous adipose tissue were above average (74 and
71% of the most expressed gene, respectively). Maximum
likelihood estimate of the minor allele frequency for the
c.136–14_136–13insC variant was 3.30% (47 heterozygous
carriers). For the power calculation, we assumed MAF of 1%
for c.136–14_136–13insC. Heritabilities, estimated through
Merlin in the Swedish sample and averaged among all al-
ternate transcripts from the same gene, were 70 and 27% for
HMGA1 and INSR, respectively. Effect sizes (r2) were es-
timated as d2/(d2 + 4) from Cohen’s d (34), calculated using
the gene transcript mean levels and CIs as observed be-
tween carriers and noncarriers of the c.136–14_136–13insC
variant in the study by Chiefari et al. (17). Average r2 values
between type 2 diabetic carriers and both type 2 diabetic
and healthy noncarriers were 0.66 for HMGA1 and 0.74 for
INSR. We observed that in the study by Chiefari et al. (17),
the type 2 diabetic noncarriers showed slightly lower
expression levels of HMGA1 and INSR than the healthy
noncarriers control subjects (P , 0.05). By assuming a
conservative lower QTL effect size of 30% in our sample
(where no type 2 diabetic carriers were included), we ob-
served a statistical power .80% at a = 0.001 to identify
a dominant effect for the c.136–14_136–13insC on the
HMGA1 and INSR gene expression levels in our sample.
The association study showed that the c.136–14_136–
13insC variant was not associated with changes in INSR
and HMGA1 expressions in the Swedish sample (P .
0.12) (Supplementary Table 5).
DISCUSSION
It has been suggested that the candidate gene approach
may be a practical and logical alternative to GWAS of
complex genetic traits (35). In fact, the study of genes with
functional polymorphisms and coding for proteins in-
volved in disease-related pathways may increase statistical
efﬁciency by minimizing multiple comparisons. Further-
more, the GWAS approach is still unable to reliably assess
the association between rare variants and complex dis-
eases such as type 2 diabetes (6,35–37). However, candi-
date gene studies have brought a majority of false-positive
results in the past, and a stringent study design is neces-
sary to reach a statistical power that allows valid con-
clusions.
Low-frequency variants with strong effects may con-
tribute to type 2 diabetes risk through their impact on in-
sulin resistance (9,17,38–41). Although the HMGA1 gene
was not part of the GWAS signals, there was some evi-
dence for its role in insulin resistance and type 2 diabetes
development (3,9,13,17,42–44).
However, our data suggest that low-frequency variants,
including c.136–14_136–13insC, are not associated with
type 2 diabetes in the French population. Furthermore, the
c.136–14_136–13insC variant had no signiﬁcant effects on
intermediate quantitative traits. Given the low statistical
power of our screening step, we cannot exclude that other
rare variants increasing type 2 diabetes susceptibility may
exist in theHMGA1 gene. Therefore, we emphasize the need
to sequence many more individuals to reliably identify rare
variants associated with common diseases.
Our data are not in line with those recently reported by
Chiefari et al. (17), who observed that the c.136–14_136–
13insC variant was strongly associated with type 2 diabetes
FIG. 2. Meta-analysis on the association between the c.136–14_136–13insC variant (or correlated polymorphism) and type 2 diabetes. na, not
applicable; summary OR 1, Italian + U.S. + French data; summary OR 2, Italian + U.S. + French + DIAGRAM data.
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risk in populations of European descent (OR 1.64–15.77). In
our study (4,906 type 2 diabetic subjects vs. 4,387 normo-
glycemic subjects), we had a statistical power of 80% to
detect a dominant OR of 1.29 for a MAF of 2.61% (type I
error = 0.05). Furthermore, large meta-analyses in Euro-
peans (including Italian control group 1 or 2) detected no
association between the c.136–14_136–13insC variant (or
correlated polymorphism) and type 2 diabetes. Of note,
strong between-study heterogeneity was observed, mainly
driven by the low allele frequencies in both groups of Italian
control subjects (Fig. 2). This heterogeneity may be due to
different inclusion criteria in the Italian, U.S., and French
studies (questionnaire, personal interview, biological
measures). In the largest Italian control group (control
group 1), Chiefari et al. (17) conducted personal interviews
to select those without a family history of type 2 diabetes or
related conditions to reduce the number of people with
insulin resistance. Apart from the fact that interviews are
not always reliable, it seems unlikely that the low allele
frequency in the Italian control group (MAF 0.22%) is only
due to an absence of family history of type 2 diabetes. In
fact, in our screening group of samples, a 13-fold higher
allele frequency was observed in French control subjects
with similar features (MAF 2.82%). Furthermore, the allele
frequency of the c.136–14_136–13insC variant tended to be
even higher in normoglycemic control subjects without
a family history of type 2 diabetes than in type 2 diabetic
case subjects with a strong family history of type 2 diabetes
(MAF 1.49%). Finally, the effect size was not different
between the screening group (ascertained for their family
history of type 2 diabetes) and the replication group (not
ascertained for their family history of type 2 diabetes) of
French individuals (Woolf test: x2 = 0.1, df = 1, P = 0.76),
contrary to what was observed in Italians by Chiefari
et al. (17).
We observed nominal deviation from the Hardy-Weinberg
equilibrium when case and control subjects were analyzed
together (P = 0.02), reﬂecting an underrepresentation of C/C
homozygotes. Chiefari et al. (17) reported that the absence
of homozygous individuals for this variant in their study was
consistent with previous observations indicating that mice
homozygous for theHmga1 null allele have reduced fertility
and die prenatally. However, the only homozygous carrier
of the c.136–14_136–13insC C allele was aged 47 years,
normoglycemic, without a family history of type 2 diabetes,
and the mother of three children. Therefore, we hypothesize
that their underrepresentation is rather due to sampling
effects (modest sample size given the low allele frequency).
Although Chiefari et al. (17) reported strong associa-
tions between the c.136–14_136–13insC variant and type 2
diabetes (1.64 , OR , 15.77), no strong effects on type 2
diabetes–related intermediate traits were detected. These
results are consistent with those of Chiefari et al. (17), who
did not observe any variation in fasting insulin levels. They
also showed a decreased expression of HMGA1 and INSR
in blood monocytes of type 2 diabetic subjects carrying the
c.136–14_136–13insC variant compared with both type 2
diabetic and healthy noncarriers, whereas no association
was identiﬁed in our study using subcutaneous adipose
tissue of normoglycemic individuals. Chiefari et al. (17)
compared a subset of case subjects carrying the c.136–
14_136–13insC variant with subsets of wild-type case and
control subjects. Their selection criteria were not speci-
ﬁed, and no comparison between control subjects (carriers
vs. noncarriers) was reported. Therefore, the expression
variation detected in monocytes may have been biased.
Furthermore, point mutations affecting INSR expression
were previously described but not sequenced in these
samples (45–47). Finally, the regulation of INSR and
HMGA1 expressions may not be the same in monocytes
and in key tissues involved in insulin resistance (e.g., ad-
ipose tissue, liver, and skeletal muscle). However, addi-
tional European individuals need to be analyzed to conﬁrm
the lack of functional effects.
In conclusion, our data suggest that the c.136–14_136–
13insC variant in the HMGA1 gene is not associated with
type 2 diabetes risk in Europeans, contrary to what was
reported by Chiefari et al. (17). The rapid development of
cost-efﬁcient next-generation sequencing should allow re-
liable detection of associations between rare mutations
and type 2 diabetes in large populations (48–50).
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